MedPath

Comparison of Clinical and Serological Differences Among Juvenile, Adult, and Late-onset Systemic Lupus Erythematosus

Not yet recruiting
Conditions
Systemic Lupus Erythematosus (SLE)
Registration Number
NCT05724940
Lead Sponsor
Sohag University
Brief Summary

Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with a highly variable presentation and course. It can affect virtually every organ of the body and many symptoms may be observed. Skin, musculoskeletal, hematologic, and serological involvement are most commonly observed. Some patients show predominately hematologic, renal, or central nervous system manifestations.

Studies have reported that juvenile-onset SLE patients tend to have a more aggressive presentation and course, with higher rates of organ involvement and lower life expectancy than adult-onset SLE patients. Late-onset SLE patients tend to have a more insidious onset of disease and tend to have less major organ involvement and more benign disease course. However, they have a poorer prognosis than patients who developed SLE before the age of 50 years, because of the generally higher frequency of comorbid diseases and higher organ damage, due to aging and longer exposure to ''classical'' vascular risk factors.

Aims of the Study:

To compare clinical and serological differences among juvenile, adult, and late-onset systemic lupus erythematosus in a cohort of SLE patients in our hospital.

Detailed Description

Methods:

All patients will be subjected to the following:

1. Thorough medical history of the patients

2. Full clinical examination including:

1. General examination and vital signs.

2. Complete rheumatological examination.

3. SLE disease activity index SLEDAI (ref).

4. SLICC damage index (ref).

3. Routine investigations (complete blood picture, erythrocyte sedimentation rate and liver functions).

4. Renal investigations:

1. Kidney functions

2. Urine analysis

3. 24 hours protein in urine and/or A/C ratio

4. Renal biopsy if indicated.

5. ANA test.

6. ANA profile for the most common 19 autoantibodies by immunoblot.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
150
Inclusion Criteria

Inclusion criteria:

  1. Patients diagnosed as SLE( Systemic lupus erythematosus )according to EULAR / ACE (European League Against Rheumatism /American College of Rheumatology )
  2. Age juvenile SLE ( Systemic lupus erythematosus )was defined as a diagnosis below the age of 18 years, and those diagnosed between 19 and 50 years of age were classified as adult SLE ( Systemic lupus erythematosus ), late onset SLE was defined as a diagnosis at more than 50 years of age).
  3. Patients with a disease duration of more than 6 months
Read More
Exclusion Criteria
  • Exclusion criteria:

    1. Patients with had other autoimmune diseases, such as rheumatoid arthritis, systemic sclerosis, mixed connective tissue disease , overlap syndrome or primary Sjogren's syndrome ,but not secondary Sjogren's syndrome or secondary antiphospholipid syndrome .
    2. Patients who are not willing to be involved in the study
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
serological differences among juvenile, adult, and late-onset systemic lupus erythematosus in a cohort of SLE patients in our hospital.1-1-2024

1. SLE disease activity index SLEDAI (ref) to assessment disease activity in patient .

2. ANA test (antinuclear antibodies ) to assessment auto-antibodies in different age grouped

laboratory differences among juvenile, adult, and late-onset systemic lupus erythematosus in a cohort of SLE patients in our hospital.1-1-2024

1. Renal biopsy for assessment kidney damage

2. urine analysis to detect albumin in urine

3. liver function to detect liver affection

hematological affection among juvenile, adult, and late-onset systemic lupus erythematosus in a cohort of SLE patients in our hospital.1-1-2024

1. cbc complete blood picture to assessment bone marrow affection

2. erythrocyte sedimentation rate to detect disease activity.

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath